News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. completes Investigational Medicinal Product Dossier (IMPD) for BNT23001, a sublingual cladribine oral dissolvable film for multiple sclerosis. IMPD is a significant regulatory milestone for the Company's lead drug candidate -
-
-
-
-
-